PPARγ agonists prevent TGFβ1/Smad3-signaling in human hepatic stellate cells

Biochemical and Biophysical Research Communications

Volumn 350, Issue 2, 2006, Pages 385-391

  Zhao, Caiyan ^a   Chen, Wei ^a   Yang, Liu ^a   Chen, Lihong ^b   Stimpson, Stephen A ^b   Diehl, Anna Mae ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Hepatic stellate cells; LFABP; PAI 1; PPAR ; PPRE; Smad3; TGF1 1

Indexed keywords

2 [1 CARBOXY 2 [4 [2 (5 METHYL 2 PHENYL 4 OXAZOLYL)ETHOXY]PHENYL] ETHYLAMINO]BENZOIC ACID METHYL ESTER; 2 [1 CARBOXY 2 [4 [2 (5 METHYL 2 PHENYL 4 OXAZOLYL)ETHOXY]PHENYL]ETHYLAMINO]BENZOIC ACID METHYL ESTER; 4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; COLLAGEN; ENZYME INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PLASMINOGEN ACTIVATOR INHIBITOR 1; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; 1,3 DIOXOLANE DERIVATIVE; 4 (5 BENZO(1,3)DIOXOL 5 YL 4 PYRIDIN 2 YL 1H IMIDAZOL 2 YL)BENZAMIDE; 4-(5-BENZO(1,3)DIOXOL-5-YL-4-PYRIDIN-2-YL-1H-IMIDAZOL-2-YL)BENZAMIDE; ACTIVIN RECEPTOR 1; BENZAMIDE DERIVATIVE; DRUG DERIVATIVE; OXAZOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; SCLEROPROTEIN; TGF BETA TYPE I RECEPTOR; TGF-BETA TYPE I RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TYROSINE;

ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LIPID STORAGE; LIVER CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STELLATE CELL; ADIPOCYTE; BIOSYNTHESIS; CELL LINE; CULTURE MEDIUM; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; GENETICS; LIVER; METABOLISM; PHOSPHORYLATION;

ACTIVIN RECEPTORS, TYPE I; ADIPOCYTES; BENZAMIDES; CELL LINE; CULTURE MEDIA; DIOXOLES; EXTRACELLULAR MATRIX PROTEINS; GENE EXPRESSION; HUMANS; LIVER; OXAZOLES; PHOSPHORYLATION; PPAR GAMMA; PROTEIN KINASE INHIBITORS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TYROSINE;

EID: 33749341729     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.09.069     Document Type: Article

References (23)

1. Liu X., Wang W., Hu H., Tang N., Zhang C., Liang W., and Wang W. Smad 3 specific inhibitor, naringenin, decreases the expression of extracellular matrix induced by TGF-beta1 in cultured rat hepatic stellate cells. Pharm. Res. 23 (2006) 82-89
2. Zhou S., Lechpammer S., Breenberger J.S., and Glowacki J. Hypoxia inhibition of adipocytogenesis in human bone marrow stromal cells requires transforming growth factor-beta/Smad3 signaling. J. Biol. Chem. 280 (2005) 22688-22696
3. Tahashi Y., Matsuzaki K., Date M., Yoshida K., Furukawa F., Sugano Y., Matsushita M., et al. Differential regulation of TGF-beta signal in hepatic stellate cells between acute and chronic rat liver injury. Hepatology 35 (2002) 49-61
4. Inagaki Y., Mamura M., Kanamaru Y., Greenwel P., Nemoto T., Takehara K., Ten Dijki P., et al. Constitutive phosphorylation and nuclear localization of Smad3 are correlated with increased collagen gene transcription in activated hepatic stellate cells. J. Cell Physiol. 187 (2001) 117-123
5. Bataller R., and Brenner D.A. Liver fibrosis. J. Clin. Invest. 2 (2005) 209-218
6. She H., Xiong S., Hhazra S., and Tsukamoto H. Adipogenic transcriptional regulation of hepatic stellate cells. J. Biol. Chem. 280 (2005) 4959-4967
7. Yata Y., Gotwals P., Koteliansky V., and Rockey D.C. Dose-dependent inhibition of hepatic fibrosis in mice by a TGF-beta soluble receptor: implications for antifibrotic therapy. Hepatology 35 (2002) 1022-1030
8. de Gouville A.C., Boullay V., Krysa G., Pilot J., Brusq J.M., Loriollo F., Gauthier J.M., et al. Inhibition of TGF-beta signaling by an ALK5 inhibitor protects rats from dimethylnitoramine-induced fibrosis. Br. J. Pharmacol. 145 (2005) 166-177
9. Yang L., Chen C.C., Kwon O.S., Liu S., McGhee J., Stimpton S., Chen L., et al. Regulation of peroxisome proliferator-activated receptor {gamma} (PPAR{gamma}) in liver fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. (2006) Epub.
10. Li Y., Wen X., Spataro B.C., Hu K., Dai C., and Liu Y. Hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-gamma agonists. J. Am. Soc. Nephrol. 17 (2006) 54-65
11. Sawai H., Liu J., Reber H.A., Hines O.J., and Eibl G. Activation of peroxisome proliferator-activated receptor-gamma decreases pancreatic cancer cell invasion through modulation of plasminogen activator system. Mol. Cancer Res. 4 (2006) 159-167
12. Ye P., Hu X., and Zhao Y. The increase in plasminogen activator inhibitor type-1 expression by stimulation of activators for peroxisome proliferator-activated receptors in human endothelial cells. Chin. Med. Sci. J. 17 (2002) 112-116
13. Marx N., Bourcier T., Sukhova G.K., Libby P., and Plutzky J. PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 546-551
14. Liang X., Kanjanabuch T., Mao S.L., Hao C.M., Tang Y.W., Declerck P.J., Hasty A.H., et al. Plasminogen activator inhibitor-1 modulates adipocyte differentiation. Am. J. Physiol. Endocrinol. Metab. 290 (2006) E103-E113
15. Tsukamoto H. Fat paradox in liver disease. Keio J. Med. 54 (2005) 190-192
16. Xu L., Hui A.Y., Albanis E., Arthur M.J., O'Byrne S.M., Blaner W.S., Mukherjee P., et al. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut 54 (2005) 142-151
17. Furukawa F., Matsuzaki K., Mori S., Tahashi Y., Yoshida K., Sugano Y., Yamagata H., et al. p38 MAPK mediates fibroenic signal through Smad3 phosphorylation in rat myofibroblasts. Hepatology 38 (2003) 879-889
18. Fu M., Zhang J., Lin Y., Zhu X., Zhao L., Ahmad M., Ehrengruber M.U., et al. Early stimulation and late inhibition of peroxisome proliferator-activated receptor gamma gene expression by transforming frowth factor beta in human aortic smoot muscle cells: role of early growth-response factor-1 (Egf-1), activator protein 1 (AP1) and Smads. Biochem. J. 370 (2003) 1019-1025
19. Sun K., Wang Q., and Huang X.H. PPAR gamma inhibits growth of rat hepatic stellate cells and TGF beta-induced connective growth factor expression. Acta Pharmacol. Sin. 27 (2006) 715-723
20. Fu M., Zhang J., Zhu X., Myles D.E., Willson T.M., Liu X., and Chen Y.E. Peroxisome proliferator-activated receptor gamma inhibits transforming growth factor beta-induced connective tissue growth factor expression in human aortic smooth muscle cells by interfering with Smad3. J. Biol. Chem. 276 (2001) 45888-45994
21. Leyland H., Gentry J., Arthur M.J., and Benyon R.C. The plasminogen-activating system in hepatic stellate cells. Hepatology 24 (1996) 1172-1178
22. Bergheim I., Guo L., Davis M.A., Duveau I., and Arteel G.E. Critical role of plasminogen activator inhibitor-1 in cholestatic liver injury and fibrosis. J. Pharmacol. Exp. Ther. 31 (2006) 592-600
23. Ma L.J., Mao S.L., Taylor K.L., Kanjanabuch T., Guan Y., Zhang Y., Brown N.J., et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 53 (2004) 336-346